Premier Path Wealth Partners’s Arbutus Biopharma ABUS Stock Holding History

Premier Path Wealth Partners’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$245K	Buy	51,183 +21,183	+71%	+$102K	0.03%	356
2026 Q2	$144K	Sell	30,000 -10,000	-25%	-$43.9K	0.02%	399
2026 Q1	$180K	Hold	40,000	–	–	0.02%	395
2025 Q4	$192K	Hold	40,000	–	–	0.02%	391
2025 Q3	$182K	Hold	40,000	–	–	0.02%	389
2025 Q2	$124K	Hold	40,000	–	–	0.02%	385
2025 Q1	$140K	Hold	40,000	–	–	0.02%	369
2024 Q4	$131K	Hold	40,000	–	–	0.02%	369
2024 Q3	$154K	Buy	40,000 +4,000	+11%	+$15.3K	0.02%	361
2024 Q2	$111K	Buy	36,000 +5,500	+18%	+$16.5K	0.02%	366
2024 Q1	$78.7K	Buy	30,500 +8,300	+37%	+$21.5K	0.01%	341
2023 Q4	$55.5K	Buy	+22,200	New	+$43.5K	0.01%	332

Other funds holding ABUS

Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

LWA

Ledgewood Wealth Advisors Exeter, New Hampshire $181M AUM 9.93% 1-Year Est. Return

AHL

Abel Hall LLC Baton Rouge, Louisiana $556M AUM 43.18% 1-Year Est. Return

Bailard Foster City, California $4.94B AUM 25.15% 1-Year Est. Return

State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return

Eastern Bank Boston, Massachusetts $6.58B AUM 23.57% 1-Year Est. Return

Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

Harbor Investment Advisory Lutherville, Maryland $1.47B AUM 24.2% 1-Year Est. Return

PWMG

Private Wealth Management Group Princeton, New Jersey $445M AUM 13.54% 1-Year Est. Return

Premier Path Wealth Partners's ABUS Position: Q3 2026 in Review

Premier Path Wealth Partners increased its Arbutus Biopharma (ABUS) stake by 71% in Q3 2026, buying an estimated $102K and bringing the position to 51,183 shares worth $245K. The position accounts for 0.03% of the portfolio, ranked #356.

Premier Path Wealth Partners first reported a position in ABUS in Q4 2023 and has held it in 12 quarters since. 13 funds tracked by Wall St. Rank hold ABUS as of Q3 2026.

Premier Path Wealth Partners held 51,183 shares of Arbutus Biopharma worth $245K as of Q3 2026.
Premier Path Wealth Partners bought 21,183 Arbutus Biopharma shares in Q3 2026, an estimated $102K.
Arbutus Biopharma made up 0.03% of Premier Path Wealth Partners's portfolio in Q3 2026, its #356 holding.
Premier Path Wealth Partners first reported a position in Arbutus Biopharma in Q4 2023 and has held it in 12 quarters since.
13 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q3 2026.

Based on Premier Path Wealth Partners's 13F filing for Q3 2026, filed 16 Oct 2026.